{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:23:23Z","timestamp":1793291003191,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2019 5M-2019-23680431"],"award-info":[{"award-number":["2019 5M-2019-23680431"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xkme.2026.101268","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:57:06Z","timestamp":1768377426000},"page":"101268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think"],"prefix":"10.1016","volume":"8","author":[{"given":"Decimo Silvio","family":"Chiarenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico E.","family":"Verrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Bigatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Caridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Spennacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xhuliana","family":"Kajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"De Bortoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-5326","authenticated-orcid":false,"given":"Andrea","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5S","key":"10.1016\/j.xkme.2026.101268_bib1","first-page":"S241","article-title":"KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children","volume":"107","author":"Kidney Disease: Improving Global Outcomes Nephrotic Syndrome In Children Work Group","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101268_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213203","article-title":"Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment","volume":"14","author":"Angeletti","year":"2023","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.xkme.2026.101268_bib3","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.xkme.2026.101268_bib4","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1007\/s00467-025-06738-w","article-title":"Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: advances, challenges, and future directions","volume":"40","author":"Angeletti","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.xkme.2026.101268_bib5","article-title":"Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength","volume":"11","author":"Bondza","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101268_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101268_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"30","key":"10.1016\/j.xkme.2026.101268_bib8","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II Trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101268_bib9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101268_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf039","article-title":"The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.xkme.2026.101268_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-024-06570-8","article-title":"Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion","volume":"40","author":"Chan","year":"2025","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2026.101268_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s40620-025-02224-6","article-title":"Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series","volume":"38","author":"Sridharan","year":"2025","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101268_bib13","first-page":"111","article-title":"Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab","volume":"56","author":"Lin","year":"2025","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101268_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jcm14010239","article-title":"Successful switch to obinutuzumab in a rituximab-intolerant child with difficult-to-treat idiopathic nephrotic syndrome","volume":"14","author":"Drozynska-Duklas","year":"2025","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.xkme.2026.101268_bib15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101268_bib16","doi-asserted-by":"crossref","first-page":"1347880","DOI":"10.3389\/fphar.2024.1347880","article-title":"One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101268_bib17","first-page":"410","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis. Reply","volume":"393","author":"Furie","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:22:50Z","timestamp":1784067770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2590059526000294"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101268","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101268"}}